Malte - anglais - Medicines Authority

smithkline beecham limited - haemophilus influenzae b; tetanus toxoid - powder and solvent for solution for infusion - haemophilus influenzae b 25 µg; tetanus toxoid 25 µg - vaccines

Australie - anglais - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - clavulanic acid, quantity: 11.4 mg/ml; amoxicillin, quantity: 80 mg/ml - oral liquid, powder for - excipient ingredients: silicon dioxide; succinic acid; colloidal anhydrous silica; aspartame; xanthan gum; hypromellose; flavour - augmentin duo 400 oral suspension is indicated in the short term treatment of the following bacterial infections when caused by sensitive organisms (see microbiology). skin and skin structure infections: urinary tract infections (complicated and uncomplicated): upper respiratory tract infections including sinusitis, otitis media: lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin. however, when there is good reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptible studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin duo 400, should not require the addition of another antibiotic due to the amoxycillin content of augmentin duo 400.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - phenoxymethylpenicillin potassium, quantity: 56.568 mg/ml (equivalent: phenoxymethylpenicillin, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: sucrose; sodium benzoate; saccharin sodium; flavour; colour - when oral therapy is required in the treatment of mild to moderately severe infections due to penicillin sensitive organisms such as penicillin sensitive staphylococci, pneumococci, gonococci and haemolytic streptococci. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. for prophylactic use in recurrent streptococcal infections including the prevention of recurrence following rheumatic fever and/or sydenham's chorea. for the prevention of bacterial endocarditis in patients with rheumatic fever and/or congenital heart disease who are about to undergo dental or upper respiratory surgery or instrumentation. oral penicillin should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower intestinal tract surgery, sigmoidoscopy or complications of childbirth.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - phenoxymethylpenicillin potassium, quantity: 28.284 mg/ml (equivalent: phenoxymethylpenicillin, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: sucrose; sodium benzoate; saccharin sodium; colour; flavour - when oral therapy is required in the treatment of mild to moderately severe infections due to penicillin sensitive organisms such as penicillin sensitive staphylococci, pneumococci, gonococci and haemolytic streptococci. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. for prophylactic use in recurrent streptococcal infections including the prevention of recurrence following rheumatic fever and/or sydenham's chorea. for the prevention of bacterial endocarditis in patients with rheumatic fever and/or congenital heart disease who are about to undergo dental or upper respiratory surgery or instrumentation. oral penicillin should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower intestinal tract surgery, sigmoidoscopy or complications of childbirth.

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

advanced probiotics international, llc - bifidobacterium longum; bifidobacterium thermophilum; enterococcus faecium; lactobacillus acidophilus; saccharomyces cerevisiae - oral powder, pre-mix - bifidobacterium longum biological-organism active 0.0 cfu/g; bifidobacterium thermophilum biological-organism active 0.0 cfu/g; enterococcus faecium biological-organism active 0.0 cfu/g; lactobacillus acidophilus biological-organism active 0.0 cfu/g; saccharomyces cerevisiae biological-organism active 0.0 cfu/g - nutrition & metabolism - calf | beef calf | bovine | calf - poddy | calf - preweaning | calf - sucker | dairy calf | neonatal calf - feed additive | improve digestive efficacy | digestive aid | feed conversion efficacy

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

advanced probiotics international, llc - bifidobacterium longum; bifidobacterium thermophilum; enterococcus faecium; lactobacillus acidophilus; saccharomyces cerevisiae - oral powder, pre-mix - bifidobacterium longum biological-organism active 0.0 cfu/g; bifidobacterium thermophilum biological-organism active 0.0 cfu/g; enterococcus faecium biological-organism active 0.0 cfu/g; lactobacillus acidophilus biological-organism active 0.0 cfu/g; saccharomyces cerevisiae biological-organism active 0.0 cfu/g - nutrition & metabolism - calf | beef calf | bovine | calf - poddy | calf - preweaning | calf - sucker | dairy calf | neonatal calf - feed additive | improve digestive efficacy | digestive aid | feed conversion efficacy

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

performance products inc - bifidobacterium longum; bifidobacterium thermophilum; bacillus subtilis; lactobacillus acidophilus; saccharomyces cerevisiae; streptococcus faecium; alpha amylase (from b. subtilis); beta glucanase; hemicellulase (b. subtilus) - oral powder, pre-mix - bifidobacterium longum biological-organism active 0.0 u; bifidobacterium thermophilum biological-organism active 0.0 u; bacillus subtilis biological-organism active 0.0 u; lactobacillus acidophilus biological-organism active 0.0 u; saccharomyces cerevisiae biological-organism active 0.0 u; streptococcus faecium vaccine-microbial active 0.0 u; alpha amylase (from b. subtilis) enzyme other 132000.0 bau/kg; beta glucanase enzyme other 9000.0 bgu/kg; hemicellulase (b. subtilus) enzyme other 8800.0 hcu/kg - nutrition & metabolism - calf | cattle | dairy cattle | beef | beef calf | bos indicus | bos taurus | bovine | breeders | buffalo | bull | bullock | calf - feed additive

Malte - anglais - Medicines Authority

glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - pertactin, pertussis filamentous, haemagglutinin, pertussis toxoid, poliovirus, inactivated, type, mahoney strain, mef, saukett strain, diphtheria toxoid, haemophilus influenzae, type b, polysaccharide, polyribosylribitol phosphate, tetanus toxoid - powder and suspension for suspension for injection - pertactin 8 µg pertussis filamentous haemagglutinin 25 µg pertussis toxoid 25 µg poliovirus (inactivated) type 1 (mahoney strain) 40 dagu/0.5ml poliovirus (inactivated) type 2 (mef-1 strain) 8 dagu/0.5ml poliovirus (inactivated) type 3 (saukett strain) 32 dagu/0.5ml diphtheria toxoid haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 10 µg tetanus toxoid - vaccines

Malte - anglais - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - tetanus toxoid, diphtheria toxoid, haemophilus type, b polysaccharide, polyribosylribitol phosphate, conjugated to, as carrier, protein, bordetella pertussis - powder and suspension for suspension for injection - diphtheria toxoid haemophilus type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus toxoid as carrier protein 10 µg bordetella pertussis 4 iu tetanus toxoid 60 iu - vaccines

États-Unis - anglais - NLM (National Library of Medicine)

merck sharp & dohme corp. - haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen (unii: luy6p8763w) (haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen - unii:luy6p8763w) - haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen 1 g in 1 g